孟鲁司特钠联合布地奈德福莫特罗治疗老年慢性阻塞性肺疾病患者的效果

Effects of Montelukast sodium combined with Budesonide and Formoterol in treatment of elderly patients with chronic obstructive pulmonary disease

目的:观察孟鲁司特钠联合布地奈德福莫特罗治疗老年慢性阻塞性肺疾病(COPD)患者的效果。方法:选取2020年5月至2022年5月该院收治的300例老年COPD患者进行前瞻性研究,按照随机数字表法将其分为对照组和观察组各150例。两组均给予常规治疗,在此基础上,对照组给予布地奈德福莫特罗治疗,观察组在对照组基础上联合孟鲁司特钠治疗,两组均治疗14 d。比较两组临床疗效,治疗前后肺功能指标[第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1/FVC]水平、血气分析指标[动脉血氧分压(PaO_(2))、动脉血二氧化碳分压(PaCO_(2))、动脉血氧饱和度(SaO_(2))]水平、炎性指标[降钙素原(PCT)、C反应蛋白(CRP)、白细胞介素-6(IL-6)]水平,以及不良反应发生率。结果:观察组治疗总有效率为98.67%(148/150),高于对照组的90.67%(136/150),差异有统计学意义(P<0.05);治疗后,观察组FEV1、FVC、FEV1/FVC水平均高于对照组,差异有统计学意义(P<0.05);治疗后,观察组PaO_(2)、SaO_(2)水平均高于对照组,PaCO_(2)水平低于对照组,差异有统计学意义(P<0.05);治疗后,观察组CRP、IL-6、PCT水平均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:孟鲁司特钠联合布地奈德福莫特罗治疗老年COPD患者可提高治疗总有效率、肺功能指标水平,改善血气分析指标水平,降低炎性指标水平,效果优于单纯布地奈德福莫特罗治疗。

Objective:To observe effects of Montelukast sodium combined with Budesonide and Formoterol in treatment of elderly patients with chronic obstructive pulmonary disease(COPD).Methods:A prospective study was conducted on 300 elderly patients with COPD admitted to the hospital from May 2020 to May 2022.According to the random number table method,they were divided into control group and observation group,150 cases in each group.Both groups were given routine treatment.On this basis,the control group was treated with Budesonide and Formoterol,while the observation group was treated with Montelukast sodium on the basis of that of the control group.Both groups were treated for 14d.The clinical efficacy,the lung function indexes[forced expiratory volume in one second(FEV1),forced vital capacity(FVC),FEV1/FVC]levels,the blood gas analysis indexes[arterial partial pressure of oxygen(PaO_(2)),arterial partial pressure of carbon dioxide(PaCO_(2)),arterial oxygen saturation(SaO_(2))]levels,the inflammatory indexes[procalcitonin(PCT),C-reactive protein(CRP),interleukin-6(IL-6)]levels,and the incidence of adverse reactions were compared between the two groups before and after treatment.Results:The total effective rate of the observation group was 98.67%(148/150),which was higher than 90.67%(136/150)of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of FEV1,FVC and FEV1/FVC in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of PaO_(2) and SaO_(2) in the observation group were higher than those in the control group,the level of PaCO_(2) was lower than that in the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of CRP,IL-6 and PCT in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Montelukast sodium combined with Budesonide and Formoterol in the treatment of the elderly patients with COPD can improve the total effective rate of treatment,the levels of lung function indexes,improve the levels of blood gas analysis indexes,and reduce the levels of inflammatory indexes.Moreover,it is superior to single Budesonide and Formoterol treatment.